Purpose: To evaluate the long‐term (up to 5 years exposure) safety and efficacy of
lacosamide as adjunctive therapy in patients with uncontrolled partial‐onset seizures taking …

Objective This study was undertaken to ascertain the natural history and patterns of
antiseizure medication (ASM) use in newly diagnosed focal epilepsy patients who were …

Objective: This article provides a short but comprehensive pharmacotherapeutic update of
adjunctive therapy with lacosamide for partial-onset seizures in adult patients. Research …

Purpose The relationship between treatment efficacy/tolerability and the dose/blood
concentration of lacosamide (LCM) was investigated in a clinical cohort of Japanese …

Background Further options for monotherapy are needed to treat newly diagnosed epilepsy
in adults. We assessed the efficacy, safety, and tolerability of lacosamide as a first-line …

Summary Purpose In 2008, lacosamide (LCM) was licensed in Europe for the adjunctive
treatment of focal-onset seizures. At that time a prospective audit was initiated at the Western …

Objectives: Lacosamide is a novel antiepileptic drug used in partial refractory epilepsy
patients. Methods: We searched retrospectively 1100 patients who have follow up in Antalya …

Purpose We describe the effectiveness of lacosamide as adjunctive therapy in patients with
epilepsy and an intellectual disability. This information is relevant, as few data exist …

Purpose The goal of this study is to report the efficacy and tolerability of lacosamide (LCM)
monotherapy, as first-line and conversion regimens, in the treatment of patients with partial …

We report our 6months of experience with adjunctive lacosamide in 25 patients with
pharmacoresistant focal epilepsy. Baseline characteristics of our patients were similar to …